Back to Search
LEONARD APPLEMAN, MD
MD
Hematology & Oncology Physician
NPI: 1861468589IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
428996(PA)
Education
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Class of 1995
Research & Publications (18)
CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation.
PMID 16969077·Cell Cycle·2006
8-other
Induction of immunologic tolerance for allogeneic hematopoietic cell transplantation.
PMID 12152983·Leuk Lymphoma·2002
6-review
CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.
PMID 11884439·J Immunol·2002
8-other
CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression.
PMID 10605005·J Immunol·2000
8-other
Identifying Muir-Torre syndrome in a patient with glioblastoma multiforme.
PMID 19028998·Neuro Oncol·2009
5-case
Renal cell carcinoma from a transplanted allograft: two case reports and a review of the literature.
PMID 18501084·Clin Genitourin Cancer·2008
5-case
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
PMID 17091249·Cancer Chemother Pharmacol·2007
3-trial
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
PMID 17075878·Cancer·2006
3-trial
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
PMID 17036355·Cancer·2006
3-trial
Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.
PMID 16503137·Eur J Cancer·2006
8-other
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
PMID 16362299·Cancer Chemother Pharmacol·2006
3-trial
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
PMID 16278405·Clin Cancer Res·2005
3-trial
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.
PMID 15986034·Br J Cancer·2005
3-trial
Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification.
PMID 12902467·J Immunol·2003
8-other
Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics.
PMID 11434720·J Mol Med (Berl)·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5115 CENTRE AVE
PITTSBURGH, PA 15232 - Phone
- (412) 692-4724
Quick Facts
- NPI
- 1861468589
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 31
- Publications
- 18
Are you this provider?
Claim Your Profile